• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by AB Science

    < Previous 1 2 Next >
    News headline image
    AB Science reports its revenues for the year 2025 and provides an update on its activities
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science provides an update on its clinical development program.
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science today reports its revenues for the first half of 2025 and provides an update on its activities
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science announces a slight delay in the publication of its 2025 half-year financial report
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science announces EMA approval of Masivet shelf-life extension to 4 years
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science reports its revenues for the year 2024 and provides an update on its activities
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science will publish its 2024 annual financial report on May 9, 2025
    From AB Science
    Via GlobeNewswire
    News headline image
    AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia
    From AB Science
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.